Peer Reviewed
Perspectives on diabetes

A1c and CVD – how low to go?

Pat Phillips
Abstract
The target levels of glycosylated haemoglobin (A1c) for people with type 2 diabetes have been questioned following the findings of three recent trials of tight glycaemic control.
Key Points

    Tight treatment targets for people with diabetes have come into question with three recently published studies identifying no cardiovascular benefit of tight glycaemic control and one of these also demonstrating an increase in mortality rate. In all three studies, glycosylated haemoglobin (A1c) levels were significantly reduced in individuals with or at high risk of cardiovascular disease (CVD). These studies have an impact on the target levels of A1c recommended to people with type 2 diabetes.

Get full access
Subscribe for full access to all articles
Buy this article

Single article purchases are temporarily unavailable due to site maintenance.

If you would like to purchase an article during this time, please email us at [email protected] with the article details and we'll assist you directly. We'll also let you know when online purchasing is available again.

Thank you for your patience and understanding.

Already a subscriber?